Engineered immune cells take on Hard-to-Treat cancers in new trial
NCT ID NCT07389239
First seen Feb 05, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This early-phase study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have not responded to standard therapies. The treatment uses the patient's own immune cells, which are genetically modified to better recognize and attack cancer cells, combined with a drug called decitabine. The goal is to find the safest dose and see if the therapy can shrink tumors or slow their growth. About 24 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.